楝酰胺|TQ0131|TargetMol

價(jià)格	￥1300	￥3250	￥5180
包裝	1mg	5mg	10mg

最小起訂量	1mg
發(fā)貨地	上海
更新日期	2026-06-29

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:楝酰胺	英文名稱:Rocaglamide
CAS:84573-16-0	品牌: TargetMol
產(chǎn)地: 美國(guó)	保存條件: Store at low temperature Powder: -20°C for 3 years \| In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
純度規(guī)格: 99.37%	產(chǎn)品類別: 抑制劑
貨號(hào): T006\|TQ0131

Product Introduction

Bioactivity

名稱	Rocaglamide
描述	Rocaglamide (Roc-A), isolated from the genus Aglaia, can be used to treat coughs, injuries, asthma, and inflammatory skin diseases. It is a potent inhibitor of NF-κB activation in T-cells.
細(xì)胞實(shí)驗(yàn)	HepG2 and Huh-7 cells (1×10^4/well) are seeded in 96-well plates in complete culture medium and incubated for 24 h. The cells are then exposed to 100 nM Rocaglamide and/or 100 ng/mL TRAIL for 24 h. The control cells are treated with DMSO at a concentration equal to that used for the drug-treated cells. The complete culture medium is then removed and MTT (200 μL, 0.5 mg/mL in 10% FBS-containing DMEM) is added to each well and the plate is incubated for 2 h at 37°C in a humidified incubator. The solution is then removed from the wells and 200 μL DMSO is added to each well prior to agitation. The absorbance at 570 nm is read using a microplate reader (Bio-Tek ELx800). The value for the vehicle-treated cells is considered to indicate 100% viability. Furthermore, a crystal violet assay is carried out. Briefly, the cells (1×10^5/mL) are seeded in a 12 well plate for 12 h and treated with TRAIL (0-100 ng/mL) and/or RocA(1-100 nM) for 12 h. The treated cells are washed with phosphate-buffered saline (PBS), fixed with 4% paraformaldehyde for 15 min, and stained using crystal violet for a further 30 min [2].
動(dòng)物實(shí)驗(yàn)	The Huh-7 cells (3×10^6), suspended in 100 μL mix (equal volumes of DMEM and Matrigel), are implanted subcutaneously into the right flank of 10 female SCID mice (6-week-old) and then randomly divided into two equal groups, one of which received an intraperitoneal injection of Rocaglamide (2.5 mg/kg in 80 μL olive oil; n=5) and the other, used as a vehicle control, received olive oil alone (n=5). These treatments are performed once daily for 32 days and the tumor volumes and body weights of the animals are measured twice a week. The tumor volumes (mm3) are calculated using the following formula: Tumor volume=LS2/2, where L is the longest diameter and S is the shortest. At the end of the experiments, the mice are sacrificed and tumor samples are harvested, fixed in formalin and embedded in paraffin as tissue sections for immunohistochemical analysis [2].
體外活性	Rocaglamide是一種有效且選擇性的熱休克因子1（HSF1）激活抑制劑，IC50約為50 nM。它通過抑制轉(zhuǎn)錄啟動(dòng)因子eIF4A的功能發(fā)揮作用，并且具有針對(duì)白血病[1,2,3]的抗癌特性。單獨(dú)使用Rocaglamide可導(dǎo)致9%的HepG2細(xì)胞和11%的Huh-7細(xì)胞發(fā)生凋亡，而與TRAIL聯(lián)合治療則分別使16%的HepG2細(xì)胞和17%的Huh-7細(xì)胞發(fā)生凋亡。然而，Rocaglamide與TRAIL的組合使用在HepG2和Huh-7細(xì)胞中引發(fā)的凋亡率分別高達(dá)55%和57%，明顯超出了簡(jiǎn)單加成效應(yīng)[2]。
體內(nèi)活性	在Rocaglamide處理組中，腫瘤體積與對(duì)照組相比為45±12%。Rocaglamide顯著抑制腫瘤生長(zhǎng)，與對(duì)照組相比有明顯差異。使用Rocaglamide治療期間，小鼠體重沒有減少，且未觀察到明顯的毒性跡象[2]。
存儲(chǔ)條件	Store at low temperature Powder: -20°C for 3 years \| In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
溶解度	DMSO : 150 mg/mL (296.7 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (1.98 mM), Sonication is recommended. Ethanol : 5 mg/mL (9.89 mM), Sonication is recommended.
關(guān)鍵字	Rocaglamide \| NF-κB \| NFκB \| NF-kB \| NFkB \| HSP \| HSF1 \| Eukaryotic Initiation Factor (eIF) \| eIF
相關(guān)產(chǎn)品	D-Psicose \| 5-Aminosalicylic Acid \| Palmitic acid sodium \| Daraxonrasib \| Zinc chloride \| Ethoxyquin \| Tamoxifen \| Triphenyl phosphate \| Chitin \| Kojic acid \| Ethyl linoleate \| N,N-Dimethylacetamide
相關(guān)庫(kù)	細(xì)胞焦亡化合物庫(kù) \| 抗乳腺癌化合物庫(kù) \| 經(jīng)典已知活性庫(kù) \| 抗癌活性化合物庫(kù) \| 抗癌化合物庫(kù) \| 已知活性化合物庫(kù) \| 生物堿類天然產(chǎn)物庫(kù) \| 激酶抑制劑庫(kù) \| 血液病分子庫(kù) \| 免疫/炎癥分子化合物庫(kù) \| 高通量篩選天然產(chǎn)物庫(kù) \| 內(nèi)質(zhì)網(wǎng)應(yīng)激化合物庫(kù)

關(guān)鍵字：楝酰胺;Rocaglamide A;Roc-A;TargetMol

公司簡(jiǎn)介

TargetMol Chemicals Inc. 總部位于馬薩諸塞州波士頓，致力于為全球生化領(lǐng)域科學(xué)家的研究提供專業(yè)的產(chǎn)品和服務(wù)。TargetMol?品牌的客戶群分布于40多個(gè)國(guó)家和地區(qū)，已發(fā)展成為全球知名的化合物庫(kù)和小分子化合物研究供應(yīng)商。 TargetMol?可提供160多種滿足不同需求的化合物庫(kù)，以及多種類型的生化試劑產(chǎn)品，包括12000多種抑制劑、16000多種天然產(chǎn)物和各類多肽、抗體、生命科學(xué)試劑盒等，此外，我們還建設(shè)有CADD（計(jì)算機(jī)輔助藥物設(shè)計(jì)）研究中心、藥理實(shí)驗(yàn)室、藥化合成平臺(tái)三大技術(shù)中心，全方位滿足客戶的定制需求。憑借我們優(yōu)質(zhì)的產(chǎn)品和服務(wù)、快速高效的全球供應(yīng)鏈和專業(yè)的技術(shù)支持，我們將有效幫助您縮短研發(fā)周期，取得更成功的結(jié)果。

成立日期	2013-04-18 （14年）	注冊(cè)資本	566.265100萬(wàn)人民幣
員工人數(shù)	100-500人	年?duì)I業(yè)額	￥ 1億以上
主營(yíng)行業(yè)	天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù)	經(jīng)營(yíng)模式	貿(mào)易,工廠,試劑,定制,服務(wù)

TargetMol中國(guó)（陶術(shù)生物）

VIP 5年

公司成立：14年
注冊(cè)資本：566.265100萬(wàn)人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營(yíng)產(chǎn)品：小分子抑制劑、藥物篩選化合物庫(kù)、藥物篩選等
公司地址：靜安區(qū)江場(chǎng)三路238號(hào)8樓

進(jìn)入店鋪

詢盤

店內(nèi)推薦

化合物 2’,3’-Dideoxy-3’-fluorocytidine|TNU0208|TargetMol

詢價(jià)

化合物 JNJ-18038683|T11720|TargetMol

￥538

化合物 Thalidomide-O-PEG4-azide|T18828|TargetMol

￥632